Dyadic International announces study published on its DYAI-100 COVID-19

Dyadic International announced that its study titled "Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel 85 Protects K18-hACE2 Mice against Lethal Virus Challenge" has been published in VACCINES, a leading peer-reviewed scientific journal as part of the Special Issue "Vaccine Candidate against SARS-CoV-2". Conducted together with leading scientists from several other organizations, this study exemplifies Dyadic’s focus building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health. "Many of the newly evolving pathogens are zoonotic viruses and they are contributing to a global threat. Safe and effective vaccines that can be developed rapidly and economically manufactured in global quantities following an outbreak are required to effectively combat these diseases. The efficacy, protection and safety data reported from this study further supports the expansive library of data – demonstrating a novel approach for the C1-cell protein production platform to be broadly applied for rapid development and manufacturing of vaccines and antibodies for both human and animals," said Dr. Ronen Tchelet, Dyadic’s Chief Scientific Officer.